Takeshi Kuwata Selected Research

tyrosine receptor (receptor, tyrosine)

1/2020	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
1/2019	Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Kuwata Research Topics

Disease

70	Neoplasms (Cancer) 02/2024 - 01/2003
36	Stomach Neoplasms (Stomach Cancer) 08/2023 - 04/2012
12	Adenocarcinoma 11/2021 - 04/2012
10	Endometrial Neoplasms (Endometrial Cancer) 11/2013 - 01/2003
8	Carcinoma (Carcinomatosis) 10/2023 - 05/2004
6	Adenocarcinoma of Lung 12/2018 - 01/2016
5	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 10/2015
5	Breast Neoplasms (Breast Cancer) 05/2023 - 05/2011
5	Hypoxia (Hypoxemia) 01/2022 - 11/2013
5	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2021 - 12/2013
3	Residual Neoplasm 01/2021 - 07/2015
3	Disease Progression 01/2021 - 01/2020
2	Turcot syndrome 08/2023 - 05/2017
2	Necrosis 04/2021 - 01/2019
2	Microsatellite Instability 03/2021 - 01/2021
2	Leukemia 01/2019 - 05/2004
2	Carcinogenesis 06/2014 - 08/2012
2	Carcinosarcoma 09/2013 - 06/2009
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 10/2023
1	Polyps 01/2023
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2023
1	Adenoma (Adenomas) 11/2021
1	Lymphoma (Lymphomas) 10/2021
1	Epstein-Barr Virus Infections 01/2021
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2020
1	Proteinuria 01/2020
1	Exanthema (Rash) 01/2020

Drug/Important Bio-Agent (IBA)

10	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2020
9	Biomarkers (Surrogate Marker)IBA 03/2021 - 12/2013
8	human ERBB2 proteinIBA 05/2023 - 01/2014
7	Proteins (Proteins, Gene)FDA Link 10/2023 - 05/2012
7	Trastuzumab (Herceptin)FDA Link 01/2021 - 05/2011
6	NivolumabIBA 02/2024 - 01/2019
6	Cadherins (E-Cadherin)IBA 01/2021 - 06/2009
6	beta CateninIBA 06/2009 - 01/2003
5	LigandsIBA 08/2023 - 05/2011
5	CytokinesIBA 01/2021 - 10/2010
5	ErbB Receptors (EGF Receptor)IBA 11/2020 - 01/2015
5	ezrinIBA 01/2018 - 01/2016
4	Formaldehyde (Formol)FDA Link 05/2023 - 01/2015
4	CateninsIBA 01/2022 - 12/2010
4	pembrolizumabIBA 01/2022 - 01/2019
4	Carbonic Anhydrase IXIBA 01/2021 - 01/2018
4	ParaffinIBA 12/2020 - 11/2012
4	KalininIBA 07/2019 - 01/2016
3	RNA (Ribonucleic Acid)IBA 02/2024 - 10/2015
3	regorafenibIBA 02/2024 - 01/2020
3	B7-H1 AntigenIBA 08/2023 - 01/2019
3	AntibodiesIBA 01/2022 - 05/2017
3	Phosphotransferases (Kinase)IBA 10/2021 - 01/2019
3	Small Interfering RNA (siRNA)IBA 03/2019 - 11/2012
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 08/2012 - 11/2006
2	Programmed Cell Death 1 ReceptorIBA 01/2022 - 11/2020
2	lenvatinibIBA 01/2022 - 01/2020
2	VimentinIBA 01/2021 - 09/2013
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 06/2018
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 01/2019
2	Monoclonal AntibodiesIBA 01/2019 - 01/2018
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 04/2015
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 05/2014
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 11/2017 - 03/2017
2	Becaplermin (PDGF-BB)FDA Link 01/2017 - 08/2010
2	CollagenIBA 01/2017 - 08/2015
2	Growth Factor ReceptorsIBA 01/2017 - 10/2016
2	Transcription Factors (Transcription Factor)IBA 08/2012 - 05/2004
2	Cyclin-Dependent Kinase Inhibitor p16IBA 09/2007 - 11/2006
2	Cyclin D1IBA 11/2006 - 05/2004
1	TAS-116IBA 02/2024
1	Fixatives (Pickling Agents)IBA 05/2023
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Prostaglandins AIBA 11/2021
1	Calmodulin-Binding Proteins (Caldesmon)IBA 10/2021
1	DesminIBA 10/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2021
1	Indicators and Reagents (Reagents)IBA 04/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	trastuzumab deruxtecanIBA 01/2021
1	napabucasinIBA 11/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Nonesterified Fatty Acids (NEFA)IBA 01/2020

Therapy/Procedure

19	Therapeutics 08/2023 - 01/2003
14	Drug Therapy (Chemotherapy) 01/2023 - 09/2012
5	Immunotherapy 02/2024 - 01/2019
4	Gastrectomy 08/2023 - 04/2012
3	Neoadjuvant Therapy 01/2021 - 09/2012
2	Colectomy 01/2023 - 10/2015
2	Genomic Medicine 01/2023 - 11/2021
1	Adjuvant Chemotherapy 08/2023
1	Precision Medicine 01/2023
1	Chemoradiotherapy 08/2021
1	Nephrectomy 04/2021